T-knife and Catalent Sign Technology Transfer and Manufacturing...

T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of...(PRWeb September 21, 2020)Read the full story at https://www.prweb.com/releases/t_knife_and_catalent_sign_technology_transfer_and_manufacturing_agreement_for_autologous_t_cell_receptor_based_cell_therapy/prweb17406593.htm

Source: PRWeb: Medical Pharmaceuticals - September 21, 2020 Category: Pharmaceuticals Source Type: news